← FDA DRUG APPROVALS

FDA ANDA · ANDA091203

LOPINAVIR; RITONAVIR

Sponsor: CIPLA LIMITED

APPLICATION
ANDA091203
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
None (Tentative Approval)

Products

LOPINAVIR; RITONAVIRNone (Tentative Approval)
LOPINAVIR 80MG, RITONAVIR 20MG · SOLUTION · ORAL

Approval history

2012-06-29OriginalLetterTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →